DRMA

NASDAQ

Dermata Therapeutics Inc.

SectorHealth CareIndustryBiotechnology: Pharmaceutical PreparationsIPO2021

News25/Ratings2

Dermata Therapeutics, Inc., a clinical-stage biotechnology company, focuses on the treatment of medical and aesthetic skin conditions. The company's lead product candidate is DMT310, a once-weekly topical product that is under clinical development for the treatment of acne vulgaris, psoriasis vulgaris, and papulopustular rosacea. It is also developing DMT410 for the treatment of hyperhidrosis and aesthetic conditions. The company was founded in 2014 and is headquartered in San Diego, California.

News · 26 weeks49-33%

2025-10-262026-04-19

Mix2190d

SEC Filings10(48%)
Other6(29%)
Market4(19%)
Insider1(5%)

Latest news

25 items

1dSEC
Amendment: SEC Form SCHEDULE 13G/A filed by Dermata Therapeutics Inc.
SCHEDULE 13G/A - Dermata Therapeutics, Inc. (0001853816) (Subject)
6dSEC
SEC Form DEFA14A filed by Dermata Therapeutics Inc.
DEFA14A - Dermata Therapeutics, Inc. (0001853816) (Filer)
6dSEC
SEC Form DEF 14A filed by Dermata Therapeutics Inc.
DEF 14A - Dermata Therapeutics, Inc. (0001853816) (Filer)
21dNEWS
Dermata Receives Notice of Acceptance of Australian Patent Application for Topical Application of Dermal Fillers with its Bioneedle Delivery System
- This would be Dermata's first patent, if issued, covering the use of its Bioneedle Delivery System ("BDS") with dermal fillers -- The Company also has allowed and issued patents in the US, Australia, and Japan covering their BDS with botulinum toxin for the treatment of hyperhidrosis -SAN DIEGO, CA / ACCESS Newswire / April 2, 2026 / Dermata Therapeutics, Inc. (NASDAQ:DRMA)(NASDAQ:DRMAW) ("Dermata" or the "Company"), a science-driven leader in dermatologic solutions, today announced the Australian Patent Office has accepted its patent application for its topical dermal filler program utilizing its BDS. The patent, entitled "Compositions for the treatment of conditions by dermal fillers," (
28dSEC
SEC Form 10-K filed by Dermata Therapeutics Inc.
10-K - Dermata Therapeutics, Inc. (0001853816) (Filer)
28dSEC
Dermata Therapeutics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
8-K - Dermata Therapeutics, Inc. (0001853816) (Filer)
28dNEWS
Dermata Therapeutics Provides Corporate Update and Reports Financial Results for the Year Ended 2025
- Dermata announced a strategic pivot to develop and commercialize direct-to-consumer ("DTC") skincare products under the brand name Tome -- Dermata plans to launch its first DTC product, our Foundational Treatment, a once-weekly mask to support a skin renewal, in the middle of 2026 -- Raised $4.125 million in gross proceeds from a private placement financing in December 2025, including participation from Dermata's Chief Executive Officer, Chief Financial Officer, and a member of the Company's management -SAN DIEGO, CA / ACCESS Newswire / March 26, 2026 / Dermata Therapeutics, Inc. (NASDAQ:DRMA, DRMAW)) ("Dermata," or the "Company"), a science-driven leader in dermatologic solutions, today h
37dINSIDER
SVP, Regulatory Affairs Bedoya-Toro Munera Maria E bought $1,270 worth of shares (1,000 units at $1.27), increasing direct ownership by 8,333% to 1,012 units (SEC Form 4)
4 - Dermata Therapeutics, Inc. (0001853816) (Issuer)
44dNEWS
Dermata Announces Appointment of Kyra Peckaitis as Vice President, Marketing
- Kyra Peckaitis will lead the launch of Dermata's recently announced Tome skincare brand -SAN DIEGO, CA / ACCESS Newswire / March 10, 2026 / Dermata Therapeutics, Inc. ("Dermata," or the "Company") (NASDAQ:DRMA)(NASDAQ:DRMAW), a science-driven leader in dermatologic solutions, today announced the appointment of Kyra Peckaitis as Vice President, Marketing. Ms. Peckaitis is a multi-disciplinary brand marketer and will lead Dermata's new brand launch, Tome Skincare. Ms. Peckaitis will oversee the marketing strategy, brand development, and consumer engagement initiatives as Tome gets ready to bring its first commercial products to market in the middle of 2026. Ms. Peckaitis brings years of expe
49dNEWS
Dermata Opens a New Chapter with the Release of Tome Skincare
-The oldest new thing in skincare -- Dermata expects to launch its first product in the middle of 2026 -SAN DIEGO, CA / ACCESS Newswire / March 5, 2026 / Dermata Therapeutics, Inc. (NASDAQ:DRMA)(NASDAQ:DRMAW) ("Dermata" or the "Company"), a science-driven leader in dermatologic solutions, today proudly announces the branding of its latest innovation in skincare: Tome, which aims to introduce "skintech at home". The Company's Tome skincare line will bring intentionally developed skincare that delivers a high level of efficacy by addressing the root causes of skin diseases and conditions. Tome is Studied Skincare™, utilizing timeless ingredients with modern innovations for today's curious skin
57dSEC
Dermata Therapeutics Inc. filed SEC Form 8-K: Leadership Update
8-K - Dermata Therapeutics, Inc. (0001853816) (Filer)
59dSEC
Amendment: SEC Form SCHEDULE 13D/A filed by Dermata Therapeutics Inc.
SCHEDULE 13D/A - Dermata Therapeutics, Inc. (0001853816) (Subject)
64dSEC
Amendment: SEC Form SCHEDULE 13G/A filed by Dermata Therapeutics Inc.
SCHEDULE 13G/A - Dermata Therapeutics, Inc. (0001853816) (Subject)
65dSEC
Amendment: SEC Form SCHEDULE 13G/A filed by Dermata Therapeutics Inc.
SCHEDULE 13G/A - Dermata Therapeutics, Inc. (0001853816) (Subject)
73dSEC
Amendment: SEC Form SCHEDULE 13G/A filed by Dermata Therapeutics Inc.
SCHEDULE 13G/A - Dermata Therapeutics, Inc. (0001853816) (Subject)
79dSEC
Dermata Therapeutics Inc. filed SEC Form 8-K: Changes in Registrant's Certifying Accountant, Financial Statements and Exhibits
8-K - Dermata Therapeutics, Inc. (0001853816) (Filer)
80dSEC
Amendment: SEC Form SCHEDULE 13D/A filed by Dermata Therapeutics Inc.
SCHEDULE 13D/A - Dermata Therapeutics, Inc. (0001853816) (Subject)
83dSEC
SEC Form EFFECT filed by Dermata Therapeutics Inc.
EFFECT - Dermata Therapeutics, Inc. (0001853816) (Filer)
84dSEC
SEC Form 424B3 filed by Dermata Therapeutics Inc.
424B3 - Dermata Therapeutics, Inc. (0001853816) (Filer)
86dSEC
Dermata Therapeutics Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits
8-K - Dermata Therapeutics, Inc. (0001853816) (Filer)
86dSEC
SEC Form 424B5 filed by Dermata Therapeutics Inc.
424B5 - Dermata Therapeutics, Inc. (0001853816) (Filer)
91dSEC
SEC Form S-3 filed by Dermata Therapeutics Inc.
S-3 - Dermata Therapeutics, Inc. (0001853816) (Filer)
93dNEWS
Dermata Receives Notice of Grant of Patent for Next-Generation Acne Treatment by Australian Patent Office
This patent grant follows the Company's U.S. issued patent, covering its Spongilla technology combination as a method to topically treat acneDermata expects to launch a new once-weekly, over-the-counter (OTC) acne treatment system, incorporating its Spongilla technology, in the middle of 2026, first in the U.S.Over 3.3 million people are diagnosed with acne in AustraliaSAN DIEGO, CALIFORNIA / ACCESS Newswire / January 20, 2026 / Dermata Therapeutics, Inc. (NASDAQ:DRMA)(NASDAQ:DRMAW) ("Dermata" or the "Company"), a science-driven leader in dermatologic solutions, today announced the Australian Patent Office has granted its patent application for its Spongilla technology combination as a metho
105dSEC
Amendment: SEC Form SCHEDULE 13D/A filed by Dermata Therapeutics Inc.
SCHEDULE 13D/A - Dermata Therapeutics, Inc. (0001853816) (Subject)
106dSEC
SEC Form D filed by Dermata Therapeutics Inc.
D - Dermata Therapeutics, Inc. (0001853816) (Filer)